IMed Consultancy’s new free whitepaper, “PMS from pain to potential: more than just ticking a box”, reveals how to transform gruelling PMS procedures into commercial benefit.

With evolving regulatory requirements such as the EU MDR 2017/745, EU IVDR 2017/746, and the UK PMS Statutory Instrument (SI), compliance has never been more demanding. However, businesses can leverage PMS to, for example:

  • Reduce their operational burden (expediting literature searches and performance evaluations).
  • Protect patient safety by proactively identifying emerging risks.
  • Gain commercial advantage by uncovering new markets, applications, and user demographics.
  • Support product innovation through data-driven improvements and claim substantiation.

Jonathan Ripley, Managing Director at IMed Consultancy, said:

“The evolution of PMS confirms that compliance can be a strategic opportunity. By adopting a comprehensive, cyclical approach to PMS, manufacturers can not only ensure patient safety but also streamline operations, enhance product development and explore new international markets.”

The new whitepaper is available to download free of charge here.

Provided by Medilink Midlands Member IMed Consultancy.

Latest Opportunities

UKHAIC opens Flexible Talent Mobility Account (FTMA) funding call

The FTMA is intended to support secondments and other activities that contribute to the mobility…

V Formation is hiring a Digital Marketing Account Manager

V Formation is seeking an experienced digital marketing account manager or senior exec to join our talented, friendly and…

Businesses can apply for the Birmingham City University micro-placement scheme

Micro-placements offer businesses the opportunity to work with a student or graduate free of charge…

Latest News

EFEC’s Role in Advancing UK-China Life Sciences Collaboration at MTI Expo 2025

Excellence First Enterprise Consultancy Ltd (EFEC) continues to play a pivotal role in bridging the…

WMHTIA realises nearly £50m in private co-investment following initial £14.5m government grant

West Midlands Health Tech Innovation Accelerator (WMHTIA) exceeds Innovation Accelerator programme targets as private co-investment…

Spending Review 2025: What £29bn for the NHS means for life sciences and medtech

Last week’s Spending Review delivered a bold signal of intent from the UK Government: the…